Product
Ataluren
Aliases
PTC124
3 clinical trials
13 indications
Indication
Genetic DiseasesIndication
Muscular DystrophyIndication
DuchenneIndication
Muscular DisordersIndication
AtrophicIndication
Muscular DiseasesIndication
Musculoskeletal DisorderIndication
Neuromuscular DisordersIndication
Nervous System DiseasesIndication
X-LinkedIndication
InbornIndication
Duchenne Muscular DystrophyIndication
Duchenne muscular dystrophyClinical trial
An Open-Label Study Evaluating the Safety and Pharmacokinetics of Ataluren in Children From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular DystrophyStatus: Completed, Estimated PCD: 2023-08-07
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label ExtensionStatus: Completed, Estimated PCD: 2022-03-05
Clinical trial
An Open-Label, Safety Study for Ataluren (PTC124) Patients With Nonsense Mutation DystrophinopathyStatus: , Estimated PCD: 2024-04-30